Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ PASC 5% Improvement Relative Risk c19hcq.org Shukla et al. CTRI/2021/06/034255 HCQ PrEP Favors HCQ Favors control
An observational multi-centric COVID-19 sequelae study among health care workers
Shukla et al., The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2022.100129, CTRI/2021/06/034255
Shukla et al., An observational multi-centric COVID-19 sequelae study among health care workers, The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2022.100129, CTRI/2021/06/034255
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 679 healthcare workers post COVID-19 discharge, 76 using HCQ prophylaxis, showing no significant difference in PASC.
risk of PASC, 5.0% lower, RR 0.95, p = 0.78, treatment 22 of 76 (28.9%), control 184 of 603 (30.5%), NNT 64, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shukla et al., 13 Dec 2022, retrospective, India, peer-reviewed, survey, 31 authors, study period July 2021 - October 2021, trial CTRI/2021/06/034255.
Contact: ajay.pharm@aiimsbhopal.edu.in.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Articles An observational multi-centric COVID-19 sequelae study among health care workers Ajay Kumar Shukla,a,* Shubham Atal,a Aditya Banerjee,a Ratinder Jhaj,a Sadasivam Balakrishnan,a Preeta Kaur Chugh,b Denis Xavier,c Atiya Faruqui,c Aakanksha Singh,c Ramasamy Raveendran,d Jayanthi Mathaiyan,d Jeevitha Gauthaman,d Urwashi I. Parmar,e Raakhi K. Tripathi,e Sandhya K. Kamat,e Niyati Trivedi,f Prashant Shah,f Janki Chauhan,f Harihar Dikshit,g Hitesh Mishra,g Rajiv Kumar,g Dinesh Kumar Badyal,h Monika Sharma,i Mamta Singla,j Bikash Medhi,k Ajay Prakash,k Rupa Joshi,k Nabendu S. Chatterjee,l Jerin Jose Cherian,l Ved Prakash Kamboj,l and Nilima Kshirsagarl a Department of Pharmacology, All India Institute of Medical Sciences, Saket Nagar, Bhopal, Madhya Pradesh, 462020, India Department of Pharmacology, Vardhman Mahavir Medical College & Safdarjung Hospital, Near AIIMS Hospital, Ansari Nagar West, New Delhi, 110029, India c Department of Pharmacology, St John’s Medical College Sarjapur - Marathahalli Rd, Beside Bank of Baroda, John Nagar, Koramangala, Bengaluru, Karnataka, 560034, India d Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, JIPMER Campus Rd, Gorimedu, Priyadarshini Nagar, Puducherry, 605006, India e Department of Pharmacology & Therapeutics, Seth G. S. Medical College & K. E. M. Hospital, Acharya Donde Marg, Parel East, Parel, Mumbai, Maharashtra, 400012, India f Department of Pharmacology, Medical College, Baroda, Vinoba Bhave Rd, Anandpura, Vadodara, Gujarat, 390001, India g Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Allahabad Bank, Bailey Rd, Sheikhpura, Patna, Bihar, 800014, India h Department of Pharmacology, Christian Medical College and Hospital, Brown Rd, CMC Campus, Ludhiana, Punjab, 141008, India i Department of Paediatrics, Christian Medical College and Hospital, Brown Rd, CMC Campus, Ludhiana, Punjab, 141008, India j Department of Psychiatry, Christian Medical College and Hospital, Brown Rd, CMC Campus, Ludhiana, Punjab, 141008, India k Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Madhya Marg, Sector 12, Chandigarh, 160012, India l Dept. of Health Research, Ministry of Health and Family Welfare, V. Ramalingaswami Bhawan, P.O. Box No. 4911. Ansari Nagar, New Delhi, 110029, India b Summary Background India has seen more than 43 million confirmed cases of COVID-19 as of April 2022, with a recovery rate of 98.8%, resulting in a large section of the population including the healthcare workers (HCWs), susceptible to develop post COVID sequelae. This study was carried out to assess the nature and prevalence of medical sequelae following COVID-19 infection, and risk factors, if any. Methods This was an observational, multicenter cross-sectional study conducted at eight tertiary care centers. The consenting participants were HCWs between 12 and 52 weeks post discharge after COVID-19 infection. Data on demographics, medical history, clinical features of COVID-19 and various symptoms of COVID sequelae was collected through specific questionnaire. The Lancet Regional Health - Southeast Asia 2023;10: 100129 Published Online XXX https://doi.org/10. 1016/j.lansea.2022. 100129 Finding Mean age of the 679 eligible participants was 31.49 ± 9.54 years. The overall prevalence of COVID sequelae was 30.34%, with fatigue (11.5%) being the most common followed by insomnia (8.5%), difficulty in breathing during activity..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit